- Active Ingredients
Product Documentation
-
View RMM (Methotrexate Patient Alert Card - Information for Patients)
Last updated on this site: 20 Sep 2022
Initial upload
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintMethotrexate 25mg/ml solution for injection
- PL Number:
- 20075/0344
- MA Holder:
- Accord Healthcare Limited
- Product Classification:
-
POM
- Product Status:
- Active
Product Documentation
-
View Patient Information Leaflet (PIL - Methotrexate 25mg/ml Solution for Injection)
Last updated on this site: 31 Mar 2025
1. To update sections 4.2, 4.4, 4.5, 4.6, 4.8 and 5.3 of the
SmPC and the PIL to be in-line with the product Information of
reference product Methotrexate 50mg/ 2ml Injection with
national procedure number: PA0822/206/002 & MAH: Pfizer
Ireland Limited.
2. To update sections 4.4 and 4.5 in SmPC and section 2 in
leaflet information in-line with the product Information of
reference product (Methotrexate 50mg/ 2ml Injection with
national procedure number: PA0822/206/002 & MAH: Pfizer
Ireland Limited).
3. To update sections 5.1 and 5.2 in SmPC in-line with the
product Information of reference product (Methotrexate 50mg/
2ml Injection with national procedure number: PA0822/206/002
& MAH: Pfizer Ireland Limited).
PIL sections updated: Sections: 2, 4, 6 and HCP section.
View Summary of Product Characteristics (SmPC - Methotrexate 25mg/ml solution for injection)Last updated on this site: 31 Mar 2025
1. To update sections 4.2, 4.4, 4.5, 4.6, 4.8 and 5.3 of the
SmPC and the PIL to be in-line with the product Information of
reference product Methotrexate 50mg/ 2ml Injection with
national procedure number: PA0822/206/002 & MAH: Pfizer
Ireland Limited.
2. To update sections 4.4 and 4.5 in SmPC and section 2 in
leaflet information in-line with the product Information of
reference product (Methotrexate 50mg/ 2ml Injection with
national procedure number: PA0822/206/002 & MAH: Pfizer
Ireland Limited).
3. To update sections 5.1 and 5.2 in SmPC in-line with the
product Information of reference product (Methotrexate 50mg/
2ml Injection with national procedure number: PA0822/206/002
& MAH: Pfizer Ireland Limited).
SmPC sections updated: 4.2, 4.4, 4.5, 4.6, 4.8, 5.1, 5.2, 6.3 & 10.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaint
For any further assistance, please get in touch.